Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 6/20 | 0.79 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.67 |
| ▸ | KDR | P35968 | 2/20 | 0.67 |
| ▸ | BRAF | P15056 | 4/20 | 0.62 |
| ▸ | ABL1 | P00519 | 8/20 | 0.61 |
| ▸ | EGFR | P00533 | 1/20 | 0.59 |
| ▸ | CSF1R | P07333 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18323290 | 0.96 | KIT (0.85) | KITFGFR1KDRBRAFABL1 | |
| SCHEMBL30080773 | 0.92 | KIT (0.93) | KITFGFR1KDRBRAFABL1 | |
| SCHEMBL17936186 | 0.92 | KIT (0.93) | KITFGFR1KDRBRAFABL1 | |
| SCHEMBL28062998 | 0.91 | KIT (0.76) | KITFGFR1KDRBRAFABL1 | |
| SCHEMBL24503732 | 0.89 | KIT (0.85) | KITFGFR1KDRBRAFABL1 | |
| SCHEMBL15907164 | 0.89 | KIT (0.73) | KITFGFR1KDRBRAFABL1 | |
| SCHEMBL4103102 | 0.88 | KIT (1.00) | KITFGFR1KDRBRAFABL1 | |
| SCHEMBL29856181 | 0.88 | KIT (1.00) | KITFGFR1KDRBRAFABL1 | |
| SCHEMBL24122650 | 0.86 | KIT (0.79) | KITFGFR1KDRBRAFABL1 | |
| SCHEMBL30011074 | 0.86 | KIT (0.79) | KITFGFR1KDRBRAFABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9522910-B2 | Protein kinase inhibitors (variants), use thereof in treating oncological diseases and a pharmaceutical composition based thereon | Obshchestvo s ogranichennoy otvetstvennostyou “Fusion Pharma” (RU) | 2016-12-20 | — | — | US | disclosed |